Prognostic significance of angiogenesis in human pancreatic cancer

SummaryTo evaluate whether angiogenic factors are of clinical relevance to actual human pancreatic cancers, we studied the intratumoral microvessel density (IMD), and PD-ECGF, VEGF protein expression in 40 pancreatic cancers using immunohistochemistry. We also investigated PD-ECGF and VEGF gene expression using reverse transcriptase-PCR (RT-PCR). Of the 40 pancreatic cancers studied, 30 carcinomas (75.0%) were evaluated to be PD-ECGF-positive and 10 carcinomas (25.0%) were determined to be PD-ECGF-negative. In contrast, 27 carcinomas (67.5%) were evaluated to be VEGF-positive, whereas 13 carcinomas (32.5%) were VEGF-negative. VEGF gene expression was moderately associated with an increase in the IMD (r2 = 0.181, P = 0.006), but no significant relationship was found between PD-ECGF gene expression and the IMD (r2 = 0.093, P = 0.059). However, tumours with positive expression for both PD-ECGF and VEGF had a higher IMD (P = 0.027). The results of the immunohistochemistry agreed well with the results of the quantitative RT-PCR. The median survival time of the hypervascular group was significantly shorter than that of the hypovascular group (P < 0.0001). In comparing the survival according to PD-ECGF and VEGF gene expression, the median survival time of the patients with positive PD-ECGF expression was significantly shorter than those with negative PD-ECGF expression (P = 0.040). Furthermore, the median survival time of the patients with positive VEGF expression was significantly shorter than those with negative VEGF expression (P = 0.048). However, the Cox multivariate analysis indicated that the IMD and VEGF expression were independent prognostic factors of the various clinicopathologic variables in pancreatic cancer patients (P = 0.0021 and P = 0.0443, respectively).

[1]  M. Kalser,et al.  Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer , 1987, Cancer.

[2]  D. Gomez,et al.  Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. , 1996, Cancer research.

[3]  A. Yoshimura,et al.  Angiogenic factor , 1992, Nature.

[4]  H. Friess,et al.  Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. , 1993, Cancer research.

[5]  S. Akiba,et al.  Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. , 1996, Journal of the National Cancer Institute.

[6]  J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[7]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[8]  T. Colby,et al.  Long‐Term Survival After Resection for Ductal Adenocarcinoma of the Pancreas Is It Really Improving? , 1995, Annals of surgery.

[9]  L. Ellis,et al.  The implications of angiogenesis for the biology and therapy of cancer metastasis , 1994, Cell.

[10]  L. Ellis,et al.  Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[12]  Vascular Endothelial Growth Factor In Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders , 1995 .

[13]  J. Fiddes,et al.  The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. , 1991, The Journal of biological chemistry.

[14]  N. Olsen,et al.  Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue , 1994, The Journal of experimental medicine.

[15]  R. Kerbel,et al.  Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. , 1995, Cancer research.

[16]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[17]  M. Toi,et al.  Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  H. Friess,et al.  Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival , 1993 .

[19]  B. Keyt,et al.  Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. , 1996, The Journal of clinical investigation.

[20]  K. Inoue,et al.  An aggressive therapeutic approach to carcinoma of the body and tail of the pancreas , 1996, Cancer.

[21]  K. Miyazono,et al.  Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. , 1992, Biochemical and biophysical research communications.

[22]  N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[23]  Samuel Hellman,et al.  Important advances in oncology , 1991 .

[24]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[25]  J. Neoptolemos,et al.  Treatment and survival in 13560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: An epidemiological study , 1995, The British journal of surgery.

[26]  H. Ohigashi,et al.  [Chemotherapy for adenocarcinoma of the pancreas]. , 1997, Nihon Geka Gakkai zasshi.

[27]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[28]  A. Cooperman,et al.  Combined modality therapy for stage II and stage III pancreatic carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D.,et al.  Regression Models and Life-Tables , 2022 .

[30]  V. Bautch,et al.  Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. , 1996, Cancer research.

[31]  H. Friess,et al.  Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  E. Abel Clinical applications of research on angiogenesis , 1996 .

[33]  H. Dvorak,et al.  Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis , 1994, The Journal of experimental medicine.

[34]  D. Carter TNM Classification of Malignant Tumors , 1998 .

[35]  Schnall Sf,et al.  Chemotherapy of adenocarcinoma of the pancreas. , 1996 .

[36]  J. Winer,et al.  Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. , 1992, The Journal of biological chemistry.

[37]  K. Miyazono,et al.  Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor , 1989, Nature.

[38]  W. McGuire,et al.  Cathepsin D and prognosis in breast cancer. , 1990, The New England journal of medicine.

[39]  H. Hamada,et al.  Molecular structure of the human cytoplasmic beta-actin gene: interspecies homology of sequences in the introns. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[40]  L. Ellis,et al.  Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. , 1996, Journal of the National Cancer Institute.

[41]  J. Folkman,et al.  Tumoral vascularity as a prognostic factor in cancer. , 1996, Important advances in oncology.

[42]  J. Isner,et al.  Reciprocal relation between VEGF and NO in the regulation of endothelial integrity , 1997, Nature Medicine.

[43]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[44]  A. Choy,et al.  Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery , 1995, The Lancet.

[45]  N. Lemoine,et al.  Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer , 1991, The Journal of pathology.

[46]  A. Ullrich,et al.  Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.

[47]  S. Gansauge,et al.  Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. , 1996, Cancer research.